The Company is pleased to announce the completion of its recent private placement of 4,258,000 units (the “Units”) at a price of $2.50 per unit for gross proceeds of $10,645,000. Each Unit consists of one common share and one non-transferable share purchase warrant (the “Warrant”). Each Warrant entitles the holder to purchase one common share […]
News
EPO Commercial Production Achieved
Dragon Pharmaceuticals Inc. is very pleased to announce that a new vector technology has been successfully applied to its EPO production plant at Nanjing Huaxin, China. The yield of the improved EPO cell line has reached 45 mg per liter, well above the Company’s initial expectation. Optimal annual EPO production from each of the bioreactors […]
New Directors Appointed
The Company is pleased to announce that Mr. Philip Yuen Pak Yiu and Dr. Yiu Kwong Sun have been appointed to the Board of Directors. Mr. Yuen has been a legal practitioner in Hong Kong since graduating from law school in London, England in 1961. In 1965, he established the law firm Yung, Yu, Yuen […]
Progress Report on Commercial Production
Dragon Pharmaceutical Inc. is pleased to announce that Nanjing Huaxin (“Huaxin”) has purchased new bioreactors and that the preparations for commercial production with its high yield EPO cell line are proceeding well. Huaxin is currently working toward increasing the annual EPO production capacity up to a level of 5 million doses while significantly reducing the […]
Dragon Closes Acquisition of Nanjing Huaxin Biotech Ltd
Dragon Pharmaceutical Inc. is pleased to announce that it has completed the acquisition of Nanjing Huaxin Biotech Ltd. (“Huaxin”) in Nanjing City, China as referred to in the previous news release dated July 7, 1999. The closing of this major transaction was marked by the issuance of a new business license by the Chinese government. […]
Dragon Received Independent Confirmation of High Yield Erythropoietin (“EPO”) Cell Line
Dragon Pharmaceutical Inc. is pleased to announce that it has received the yield results of an independent test of the EPO cell line constructed by the Company’s Chinese subsidiary using CHO (Chinese Hamster Ovary) cells. The EPO cell line was tested at the Beijing Institute of Microbiology and Epidemiology, an independent lab. The yield of […]
Acquisition of the Largest Erythropoietin (“EPO”) Producer in China
Dragon Pharmaceutical Inc. is pleased to announce that its subsidiary, Sanhe Kailong Biopharmaceutical Co., Ltd. (“Kailong”), has entered into an agreement to acquire a 75% interest in Nanjing Huaxin Biopharmaceutical Ltd. (“Huaxin”) of China. This strategic agreement provides Dragon with both the drug license and production permit for the manufacture and marketing of EPO in […]
Dragon Pharmaceuticals Announces Completion of Private Placement
Dragon Pharmaceuticals Inc. is pleased to announce the completion of the private placement of 2,000,000 common shares at US$0.50 per share. The proceeds will be used to fund the on-going development of the Company’s biotech projects in China. The working capital of the Company currently stands at approximately US$1.4 million. The Company has invested approximately […]
